Appointment of New Chief Executive Officer

John's career spans twenty years, with extensive experience leading and working with international healthcare companies as an executive manager, board member, private equity investor and corporate financier, with a strong focus on emerging medical technologies.  Leading up to his appointment, John served as a Non-Executive Director to Quanta for four years following the initial investment in the company he led at NBGI Ventures ("NBGI"), a leading venture capital fund investing in medical technology companies.  

As an Investment Director at NBGI, John was also closely involved-both as a board member and a venture investor-with a number of other innovative medtech companies such as Cellnovo Ltd (UK), Symetis SA (Switzerland), Advanced Cardiac Therapeutics Inc (US), and BoneSupport (Sweden). In this role, John was involved in a range of finance, strategy, business development and operational matters, guiding these emerging companies through regulatory approvals and commercialisation for new medical products. John is a graduate of the University of Chicago. He currently sits on the i4i selection panel for the NHS National Institute for Health Research and is a regular speaker and panellist at various global medtech and investment conferences, including the Economist Pharma Summit in London in 2014.

Commenting upon his appointment as Chief Executive Office of Quanta, John E. Milad said: "I am delighted to lead Quanta as the Company enters its next phase of development, when we will soon obtain CE Mark and then commence market introduction for our first product. The forthcoming year promises to be one of great strategic and operational importance, as we initiate the clinical launch of our unique high-performance, portable, cartridge-based dialysis system."  

"I am particularly excited about the path ahead for Quanta. Our technology shows great promise to help millions of renal patients around the world to enjoy a better quality of life by enabling and supporting a broad range of dialysis modalities across the full continuum of care, from the clinic to the home."

Johan de Ruiter, Chairman of Quanta, added: "The Board is delighted to welcome John as Quanta's new CEO. We have known John for many years as a Director of the Company and, as a healthcare expert, he has been instrumental in helping us to develop Quanta operationally and strategically. John has valuable experience with commercialisation of innovative medical devices and I am therefore extremely confident that he will lead Quanta towards delivering significant benefits to patients, healthcare providers and payors across the globe."  

"I would also like to thank Martin Johnson, our departing CEO and founder, for all the hard work and dedication he has shown to Quanta. His original idea and engineering skills have led to a break-through innovation in dialysis.  We look forward to being able to continue to use his expertise and support as the company transitions to its next phase."

About Quanta

Quanta is a pioneering UK-based medical devices company focusing on the development and commercialisation of a novel cartridge-based haemodialysis system designed to be broadly used across the full continuum of care, both in the clinic and at home.  Quanta's system uniquely combines the advantages of a portable, easy-to-use system with the high performance and flexibility of larger clinical machines.  Quanta is privately owned and based in Alcester, UK.  Quanta was founded in 2008 as a spin-out from IMI plc, with funding led by a group of venture capital investors specialised in the life sciences: NBGI, Seroba Kernel, Wellington Partners and BrainsToVentures.

About End Stage Renal Disease and Haemodialysis:

Lifestyle choices, modern diet and increased life expectancy are all negatively impacting renal health across the globe. End Stage Renal Disease affects millions of patients worldwide. Haemodialysis is a lifesaving treatment delivered to an estimated 2 million people globally-with this figure expected to double in the next decade.  At present, haemodialysis is primarily provided by specialist clinics and centres. Issues of patient benefit, cost and clinic capacity are driving the growth of home and self-care modalities of haemodialysis. A number of studies have shown that 30-40% of patients would be capable of performing self-dialysis (compared with current practice in most western countries, where very few haemodialysis patients have this option) and that more frequent and longer dialysis improves health, longevity and quality of life. A major factor limiting the growth of self-care and home haemodialysis is the lack of convenient, portable and easy-to-use dialysis systems. Quanta's haemodialysis system addresses this market need while at the same time saving set-up and nursing time when used in-centre.

For more information about Quanta, please contact:

Quanta
John E. Milad,
Chief Executive Officer
T: +44(0)1789-400043
E: [email protected]

Consilium Strategic Communications
Amber Bielecka/ Mary-Jane Elliott/ Matthew Neal/ Lindsey Neville
T: +44(0)20-7920-2354
E: [email protected]